EGFR and neoplasm: Rapid changes in glycolysis with EGFR TKI are coupled to robust inhibition of EGFR signaling.22 Thus, we asked whether the distinct FDG responses and outcomes with the osimertinib on the tumor xenografts could be explained by their unique pharmacodynamic properties on EGFR signaling.